Skip to content

Prospective, single-group, multicenter clinical study to evaluate the safety and efficacy of sterile pulmonary arterial valves and delivery systems

To evaluate the safety and efficacy of pulmonary arterial valves and delivery systems

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-17013126
Enrollment
Unknown
Registered
2017-10-26
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial valves

Interventions

Sponsors

Union Hospital,Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with New York Heart Association (NYHA) grade II and above, meet the first standard Patients with New York Heart Association (NYHA) grade I, meet the first and second. 1. meet one of the following conditions Pulmonary valve regurgitation score = 30%?measured by Cardiac magnetic resonance imaging (MRI); Moderate (3+) to severe (4+) pulmonary arterial valves regurgitation measured by transthoracic ultrasonography; 2. Patients with New York Heart Association (NYHA) grade I should meet one of the following conditions Right ventricular end-diastolic volume index (RVEDVI) = 150 mL / m2 measured by cardiac magnetic resonance imaging (MRI); Right ventricular end-diastolic volume (RVEDV) and left ventricular end-diastolic volume (LVEDV) ratio = 2.0 measured by cardiac magnetic resonance imaging (MRI).;Inclusion criteria: Inclusion criteria: Patients with New York Heart Association (NYHA) grade II and above, meet the first standard Patients with New York Heart Association (NYHA) grade I, meet the first and second. 1. meet one of the following conditions Pulmonary valve regurgitation score = 30%?measured by Cardiac magnetic resonance imaging (MRI); Moderate (3+) to severe (4+) pulmonary arterial valves regurgitation measured by transthoracic ultrasonography; 2. Patients with New York Heart Association (NYHA) grade I should meet one of the following conditions Right ventricular end-diastolic volume index (RVEDVI) = 150 mL / m2 measured by cardiac magnetic resonance imaging (MRI); Right ventricular end-diastolic volume (RVEDV) and left ventricular end-diastolic volume (LVEDV) ratio = 2.0 measured by cardiac magnetic resonance imaging (MRI).;Inclusion criteria: Inclusion criteria: Patients with New York Heart Association (NYHA) grade II and above, meet the first standard Patients with New York Heart Association (NYHA) grade I, meet the first and second. 1. meet one of the following conditions Pulmonary valve regurgitation score = 30%?measured by Cardiac magnetic resonance imaging (MRI); Moderate (3+) to severe (4+) pulmonary arterial valves regurgitation measured by transthoracic ultrasonography; 2. Patients with New York Heart Association (NYHA) grade I should meet one of the following conditions Right ventricular end-diastolic volume index (RVEDVI) = 150 mL / m2 measured by cardiac magnetic resonance imaging (MRI); Right ventricular end-diastolic volume (RVEDV) and left ventricular end-diastolic volume (LVEDV) ratio = 2.0 measured by cardiac magnetic resonance imaging (MRI).;Inclusion criteria: Inclusion criteria: Patients with New York Heart Association (NYHA) grade II and above, meet the first standard Patients with New York Heart Association (NYHA) grade I, meet the first and second. 1. meet one of the following conditions Pulmonary valve regurgitation score = 30%?measured by Cardiac magnetic resonance imaging (MRI); Moderate (3+) to severe (4+) pulmonary arterial valves regurgitation measured by transthoracic ultrasonography; 2. Patients with New York Heart Association (NYHA) grade I should meet one of the following conditions Right ventricular end-diastolic volume index (RVEDVI) = 150 mL / m2 measured by cardiac magnetic resonance imaging (MRI); Right ventricular end-diastolic volume (RVEDV) and left ventricular end-diastolic volume (LVEDV) ratio = 2.0 measured by cardiac magnetic resonance imaging (MRI).;Inclusion criteria: Inclusion criteria: Patients with New York Heart Association (NYHA) grade II and above, meet the first standard Patients with New York Heart Association (NYHA) grade I, meet the first and second. 1. meet one of the following conditions Pulmonary valve regurgitation score = 30%?measured by Cardiac magnetic resonance imaging (MRI); Moderate (3+) to severe (4+) pulmonary arterial valves regurgitation measured by transthoracic ultrasonography; 2. Patients with New York Heart Association (NYHA) grade I should meet one of the following conditions Right ventricular end-diastolic volume index (RVEDVI) = 150 mL / m2 measured by cardiac magnetic resonance imaging (MRI); Right ventricular end-diastolic volume (RVEDV) and left ventricular end-diastolic volume (LVEDV) ratio = 2.0 measured by cardiac magnetic resonance imaging (MRI).

Exclusion criteria

Exclusion criteria: Exclusion criteria: (1) Anatomical assessment is not appropriate, including the vascular entry can not fed the valve or RVOT-PA can not place the valve, or preoperative examination prompted the valve stent compression of the coronary artery; (2) Pulmonary hypertension [mean pressure > 30mmHg (1 mmHg = 0.133kPa)] measured by right heart catheter intervention; (3) Acute decompensated heart failure; (4) A history of infective endocarditis or currently suffering from active infection of endocarditis; (5) Known to be allergic to aspirin or heparin; (6) Life expectancy is less than 1 year; (7) women of childbearing age with urine or serum pregnancy test positive; (8) Participating in clinical trials of other unlisted products; (9) the patient or guardian is unwilling or unable to provide written informed consent or disobey the follow-up request; (10) According to the researchers to determine, the patient is not suitable for pulmonary valve implantation;;Exclusion criteria: Exclusion criteria: (1) Anatomical assessment is not appropriate, including the vascular entry can not fed the valve or RVOT-PA can not place the valve, or preoperative examination prompted the valve stent compression of the coronary artery; (2) Pulmonary hypertension [mean pressure > 30mmHg (1 mmHg = 0.133kPa)] measured by right heart catheter intervention; (3) Acute decompensated heart failure; (4) A history of infective endocarditis or currently suffering from active infection of endocarditis; (5) Known to be allergic to aspirin or heparin; (6) Life expectancy is less than 1 year; (7) women of childbearing age with urine or serum pregnancy test positive; (8) Participating in clinical trials of other unlisted products; (9) the patient or guardian is unwilling or unable to provide written informed consent or disobey the follow-up request; (10) According to the researchers to determine, the patient is not suitable for pulmonary valve implantation;;Exclusion criteria: Exclusion criteria: (1) Anatomical assessment is not appropriate, including the vascular entry can not fed the valve or RVOT-PA can not place the valve, or preoperative examination prompted the valve stent compression of the coronary artery; (2) Pulmonary hypertension [mean pressure > 30mmHg (1 mmHg = 0.133kPa)] measured by right heart catheter intervention; (3) Acute decompensated heart failure; (4) A history of infective endocarditis or currently suffering from active infection of endocarditis; (5) Known to be allergic to aspirin or heparin; (6) Life expectancy is less than 1 year; (7) women of childbearing age with urine or serum pregnancy test positive; (8) Participating in clinical trials of other unlisted products; (9) the patient or guardian is unwilling or unable to provide written informed consent or disobey the follow-up request; (10) According to the researchers to determine, the patient is not suitable for pulmonary valve implantation;;Exclusion criteria: Exclusion criteria: (1) Anatomical assessment is not appropriate, including the vascular entry can not fed the valve or RVOT-PA can not place the valve, or preoperative examination prompted the valve stent compression of the coronary artery; (2) Pulmonary hypertension [mean pressure > 30mmHg (1 mmHg = 0.133kPa)] measured by right heart catheter intervention; (3) Acute decompensated heart failure; (4) A history of infective endocarditis or currently suffering from active infection of endocarditis; (5) Known to be allergic to aspirin or heparin; (6) Life expectancy is less than 1 year; (7) women of childbearing age with urine or serum pregnancy test positive; (8) Participating in clinical trials of other unlisted products; (9) the patient or guardian is unwilling or unable to provide written informed consent or disobey the follow-up request; (10) According to the researchers to determine, the patient is not suitable for pulmonary valve implantation;;Exclusion criteria: Exclusion criteria: (1) Anatomical assessment is not appropriate, including the vascular entry can not fed the valve or RVOT-PA can not place the valve, or preoperative examination prompted the valve stent compression of the coronary artery; (2) Pulmonary hypertension [mean pressure > 30mmHg (1 mmHg = 0.133kPa)] measured by right heart catheter intervention; (3) Acute decompensated heart failure; (4) A history of infective endocarditis or currently suffering from active infection of endocarditis; (5) Known to be allergic to aspirin or heparin; (6) Life expectancy is less than 1 year; (7) women of childbearing age with urine or serum pregnancy test positive; (8) Participating in clinical trials of other unlisted products; (9) the patient or guardian is unwilling or unable to provide written informed consent or disobey the follow-up request; (10) According to the researchers to determine, the patient is not suitable for pulmonary valve implantation;

Design outcomes

Primary

MeasureTime frame
Pulmonary artery regurgitation grade measured by ultrasound;;the mean right ventricular outflow tract (RVOT) pressure measured by ultrasound;Pulmonary Regurgitation grade (PR) and ventricular volume (RVEDV; RV-EDVI; RV-EF; measured by MRI;New York Heart Association functional grade;

Countries

China

Contacts

Public ContactXiaoke Shang;Xiaoke Shang;Xiaoke Shang;Xiaoke Shang;Xiaoke Shang ;;;;

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Union Hospital, Tongji Medical College, Huazhong University of Science and Technology;Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

14236338@qq.com;14236338@qq.com;14236338@qq.com;14236338@qq.com;14236338@qq.com+86 18827338233;+86 18827338233;+86 18827338233;+86 18827338233;+86 18827338233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026